Startseite Kongressberichte & Archiv BCC2019 Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I

Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I

Chairs: Daniel F. Hayes (USA), Karen Gelmon (Canada)

  • Adjuvant and neoadjuvant chemotherapy in patients with ER positive and HER2 negative breast cancer (Angelo Di Leo, Italy)
  • Adjuvant endocrine therapy for premenopausal women: Risk stratification, type and duration (Prudence Francis, Australia)
  • Adjuvant endocrine therapy in postmenopausal women: Risk stratification, type and duration (Harold J. Burstein, USA)
  • Estimating the magnitude of clinical benefit of bisphosphonates and denosumab in the adjuvant setting (Robert Coleman, UK)

BCC2019 PARTICIPANT: PASSWORD in BCC e-mail from March 23.